Caution before canonisation: a clinical and implementation science perspective on psychedelics.

Abstract

Recent advances in psychedelic research have renewed interest in the potential therapeutic role of psychedelic-assisted interventions in psychiatry. Early clinical trials suggest that compounds such as psilocybin and MDMA, administered within structured therapeutic frameworks, may produce rapid symptom improvements for conditions including depression, post-traumatic stress disorder, and substance use disorders. While these findings are scientifically promising, the current evidence base remains characterized by methodological and translational limitations. Many studies involve small samples, short follow-up periods, functional unblinding, and heterogeneous safety reporting, which complicate causal interpretation and generalizability. In the present paper, we examine psychedelic therapies through clinical, methodological, ethical, and implementation science lenses. We argue that current trials primarily demonstrate proof-of-concept efficacy under controlled conditions rather than readiness for large-scale clinical adoption. Responsible translation therefore requires stronger evidence regarding durability, safety monitoring, comparative effectiveness, and real-world implementation. Psychedelic therapies represent an important emerging research direction, but continued rigorous evaluation and improved implementation of established evidence-based interventions remain central to addressing mental disorders.